Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR-T therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents), or intensive CTX (≥3 CTX agents or high-dose therapy with stem cell transplantation). We found associations between the number of CTX agents used and impaired post-CAR-T hematopoietic reconstitution, evident across hematopoietic cell lineages and particularly manifesting during the late post-CAR-T period. Intensive CTX bridging was associated with a prolonged time to neutrophil and platelet recovery, distinct patterns of hematopoietic recovery (eg, an intermittent phenotype characterized by a second drop), an increased susceptibility to severe infections and a significantly increased risk for severe late cytopenias in univariate and multivariate models. Taken together, these results highlight that bridging intensity distinctly shapes the trajectory of hematopoietic recovery after BCMA CAR-T therapy. Targeted and novel immunotherapies could provide alternatives for bridging, and high-risk patients may particularly benefit from enhanced monitoring, prophylaxis, and supportive care.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-04-23
DOI
https://doi.org/10.1182/bloodadvances.2024015732
Citations
7
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
7.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Xiang Zhou, Luciana V. Gatti, David Sedloev, Hermann Einsele et al.
7 citations
Blood Advances
CAR-T cell therapy research
7.32
article

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Xiang Zhou, Luciana V. Gatti, David Sedloev, Hermann Einsele, Michael Schmitt, Leo Rasche, Carsten Müller‐Tidow, Patrick Costello, Jan Frenking, Omar Nadeem, Christian Michel, Niels Weinhold, Joseph Kauer, Kai Rejeski, Hartmut Goldschmidt, Marc S. Raab, Klaus K Herfarth, K. Elias, Adam S. Sperling, Sandra Sauer, Mirco Friedrich, Michael Hundemer, Peter Dreger, Thomas Hielscher, Nikhil Munshi, Max S. Topp, V. Wagner, Anita Schmitt
article en
7 citations

Abstract

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR-T therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents), or intensive CTX (≥3 CTX agents or high-dose therapy with stem cell transplantation). We found associations between the number of CTX agents used and impaired post-CAR-T hematopoietic reconstitution, evident across hematopoietic cell lineages and particularly manifesting during the late post-CAR-T period. Intensive CTX bridging was associated with a prolonged time to neutrophil and platelet recovery, distinct patterns of hematopoietic recovery (eg, an intermittent phenotype characterized by a second drop), an increased susceptibility to severe infections and a significantly increased risk for severe late cytopenias in univariate and multivariate models. Taken together, these results highlight that bridging intensity distinctly shapes the trajectory of hematopoietic recovery after BCMA CAR-T therapy. Targeted and novel immunotherapies could provide alternatives for bridging, and high-risk patients may particularly benefit from enhanced monitoring, prophylaxis, and supportive care.

Blood AdvancesVol. 9(16)
Broad Institute (US), Brigham and Women's Hospital (US), Memorial Sloan Kettering Cancer Center (US), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), National Center for Tumor Diseases (DE), Dana-Farber Cancer Institute (US), Universitätsklinikum Würzburg (DE), Ludwig-Maximilians-Universität München (DE)
U.S. Department of Defense, Amgen, Pfizer, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, Array BioPharma, Johns Hopkins University, Incyte, Chugai Pharmaceutical, National Cancer Institute, Cilag
Good health and well-being
Openalex Percentile: Top 3%
CAR-T cell therapy research
7.32
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.